CN104910083A - Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof - Google Patents

Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof Download PDF

Info

Publication number
CN104910083A
CN104910083A CN201510409626.2A CN201510409626A CN104910083A CN 104910083 A CN104910083 A CN 104910083A CN 201510409626 A CN201510409626 A CN 201510409626A CN 104910083 A CN104910083 A CN 104910083A
Authority
CN
China
Prior art keywords
compound
preparation
formula
application
alkoxylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510409626.2A
Other languages
Chinese (zh)
Inventor
蔡子洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Original Assignee
Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foshan Saiweisi Pharmaceutical Technology Co Ltd filed Critical Foshan Saiweisi Pharmaceutical Technology Co Ltd
Priority to CN201510409626.2A priority Critical patent/CN104910083A/en
Publication of CN104910083A publication Critical patent/CN104910083A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the medicine field related to 2-diabetes mellitus, in particular to 11beta-HSD1 inhibitor with alkoxylphenyl triazole sulfoxide structure, a preparation method thereof and an application for preparing medicine for treating 2-diabetes mellitus. FORMULA (as shown in the description), wherein R is selected from C1-C3 alkyl.

Description

Alkoxyphenyl radical triazole sulfoxide type 11 beta-HSD 1 inhibitors, preparation method and its usage
Technical field
The present invention relates to the pharmaceutical field of diabetes B treatment.Specifically, the present invention relates to medicative class alkoxyphenyl radical triazole sulfoxide type 11 beta-HSD 1 inhibitors of diabetes B tool, its preparation method, and the purposes in pharmacy.
Background technology
Diabetes are the lysis caused by multi-pathogenesis, have influence on the population of global 6%-7%.Expect 2025, number of patients can double again and reach 300,000,000.The most important clinical pathologic characteristic of diabetes is that plasma glucose (blood sugar) concentration increases.It is the major cause leading diabetogenic various clinical symptom that blood sugar concentration increases.Unsteered hyperglycemia causes many diabetic complications, comprises ephrosis, neuropathy, retinopathy, hypertension, cerebral ischemia and coronary heart disease etc.Therefore, the key that blood sugar is treatment and prevent diabetes and complication thereof is reduced.
11-beta-hydroxy steroid dehydrogenase type 1 (11 β-HSD1) is the Effective target site of the symptom relevant with improving other diabetes to glycemic control in the past few years confirmed.Research is determined, glucocorticoid activity does not control by means of only secretion hydrocortisone and hands over control in tissue mutually horizontally through in the cell of active Cortisol and nonactive cortisone, this mutual traffic is crossed through 11-beta-hydroxysteroid dehydrogenase, namely 11 β-HSD1 (it activates cortisone) and 11 β-HSD-2 (its deactivation hydrocortisone) complete (Sandeep TC & Walker BR, Trends Endocrinol & Metab., 2001,12,446-453).This mechanism may be important for people, several in carbenoxolone (the anti-stain of a kind of suppression 11 β-HSD1 and-2 is die young medicine) treatment at first, this treatment causes insulin sensitivity to improve, illustrate 11 β-HSD1 by reduce active glucocorticoid organize horizontal Effective Regulation insulin action (WalkerBR et al.J.Clin.Endocrinol.Metab., 1995,80,3155-3159).
Many have insulin resistance but the patient not developing into diabetes B also has development to be called the risk of the symptom of " syndrome X " or " metabolic syndrome ".Syndrome X or metabolic syndrome take insulin resistance as feature, and with abdominal obesity, hyperinsulinemia, hypertension, low high-density lipoprotein (HDL) (HDL) and high vldl (VLDL).No matter whether these patients, develop into obvious diabetes, all have the risk of the above-mentioned cardiovascular complication of the development of increase.11 beta-HSD 1 inhibitors, except having therapeutic action ten thousand to diabetes B, increase the cognition enhancing needed for lipid disorders, obesity, atherosclerosis, Alzheimer and associated conditions, hypertension, intraocular pressure, promote that wound healing and metabolic syndrome etc. all have certain treatment and prophylactic effect.
The invention discloses 11 beta-HSD 1 inhibitors of a class containing alkoxyphenyl radical triazole sulfoxide structure, these compounds can be used for the medicine preparing treatment diabetes B and relative disease thereof.
Summary of the invention
An object of the present invention is to provide a kind of 11 beta-HSD 1 inhibitors with the excellent activity of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
Another object of the present invention is to provide compound containing general formula I as effective constituent, and the application in treatment diabetes B.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein, R is selected from C 1-C 3alkyl.
The compound of preferred formula I has following structure,
Compound of Formula I of the present invention is synthesized by following route:
Compound IV is according to document route synthesis (US20130345271).
Compound II per is at low temperatures first through n-BuLi process, and the phenyl lithium obtained is again at BF 3et 2with (S)-polychlorinated dibenzo-furans generation substitution reaction under O catalysis, obtain compound III; Compound III and compound IV are reacted, and obtain compound V; Compound V obtains Compound I through oxidizing; The definition of R as previously mentioned.
Compound of Formula I of the present invention has 11 β-HSD1 restraining effect, can be used as effective constituent for the preparation of diabetes B medicine.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-500mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I-1
A. the synthesis of compound III-1
Compound II per-1 (1.71g; 10mmol) be dissolved in the THF of 20mL drying; be cooled to-78 DEG C under nitrogen protection; induction stirring; hexane solution (the 6.25mL of the n-BuLi of 1.6M is slowly dripped with syringe; 10mmol), dropwise rear reaction mixture and continue stirring at such a temperature 1 hour.Boron trifluoride diethyl etherate (1.42g is slowly dripped with syringe, solution 10mmol) prepared with 1mL THF, after dropwising, (1.11g is slowly dripped again with syringe, 12mmol) the solution of the THF preparation of (S)-polychlorinated dibenzo-furans and 1mL drying, after dropwising, compound of reaction is slowly warmed up to room temperature, and at room temperature stirring is spent the night, TLC detection reaction completes.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and resistates uses purification by silica gel column chromatography, obtains compound III-1, white solid, ESI-MS, m/z=185 ([M+H] +).
B. the synthesis of compound V-1
Compound III-1 (1.29g, 7mmol), compound IV-1 (1.55g, 7mmol) and solid K 2cO 3(2.90g, 21mmol) adds in 20mL DMF, room temperature for overnight, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and resistates uses purification by silica gel column chromatography, obtains compound V-1, white solid, ESI-MS, m/z=371 ([M+H] +).
C. the synthesis of Compound I-1
Compound V-1 (1.85g, 5mmol) is dissolved in 20mL CH 2cl 2in, ice-water bath cooling is lower stirs, and slowly adds metachloroperbenzoic acid (mCPBA, 1.04g, 6mmol), and after adding, stirred at ambient temperature 1 hour, TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH 2cl 2(60mL × 3) extract, and merge extraction phase, use saturated NaHCO successively 3with salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and resistates uses purification by silica gel column chromatography, obtains Compound I-1, white solid, ESI-MS, m/z=387 ([M+H] +).
embodiment 2-6
With reference to the method for embodiment 1, synthesize following compounds.
embodiment 7 Compound ira vitro is to the restraining effect of 11 β-HSD1
The vitro enzyme activity of test compound is evaluated through scintillation proximity assay (SPA).The determined compound 11 β-HSD1 enzymes optimizing cortisone substrate, NADPH cofactor and structural formula (I) are made to carry out to the conversion of hydrocortisone 37 DEG C of cultivations.After incubation, the preparation of the SPA pearl applied by the a-protein with the pre-mixing of anti-hydrocortisone monoclonal antibody and nonspecific 11 β-HSD inhibitor such as 18 β-glycyrrhetinic acids adds in each hole.Mixture, 15 DEG C of vibrations, reads with the liquid scintillation counter being suitable for 96 orifice plates subsequently.Calculate relative to non-suppression control wells and suppress percentage ratio, obtain IC 50curve.Specifically, add in the hole of specifying on 96 orifice plates 40 μ L substrates (25nM in 50mM HEPES damping fluid [ 3h]-cortisone+1.25mM NADPH, pH 7.4).Compound is dissolved in DMSO with 10mM, 50 times of dilutions successively in DMSO.Material 4 times of titration subsequently of dilution 7 times.In substrate, add the titrated compound of 1 μ L respectively subsequently in duplicate.For starting reaction, in each hole, add 11 β-HSD1 microsomes that 10 μ L obtain by Chinese hamster ovary celI transfection thing with the feedstock conversion producing about 10% with suitable concentration.For finally calculating suppression percentage ratio, add in a series of holes of the minimum and maximum test of expression: the one group of material not having compound or enzyme (background) containing substrate, containing substrate and enzyme without any another group material (peak signal) of compound.Plate is centrifugal to collect reactant simply under the low speed in centrifuges, with adhesive tape sealing, slowly mixes, cultivates 2 hours at 37 DEG C.After incubation, in each hole, add SPA pearl and formula (I) compound that the anti-hydrocortisone monoclonal antibody of 45 μ L suspends in advance.Plate is resealed, 15 DEG C of gentle vibrations more than 1.5 hours.Data are collected in plate base liquid scintillation counter.For controlling the suppression that anti-hydrocortisone antibody/hydrocortisone combines, will with 1.25nM [ 3h-] hydrocortisone do in target substrate add in the single hole of specifying.In each such hole, add 200 μMs of compounds of 1 μ L, replace enzyme with 10 μ L damping fluids simultaneously.The suppression of any calculating is incorporated into the interference of the antibody on SPA pearl to hydrocortisone owing to compound.
Test result sees the following form.
Compound IC 50(nM)
Embodiment 1 compound 9.7
Embodiment 2 compound 10.5
Embodiment 3 compound 18.9
Embodiment 4 compound 11.3
Embodiment 5 compound 12.4
Embodiment 6 compound 13.1
As can be seen from upper table result, compound of the present invention has very strong restraining effect to 11 β-HSD1, can as preparation treatment diabetes B medicine.

Claims (4)

1. there is the compound of general formula I,
Wherein, R is selected from C 1-C 3alkyl.
2. the compound of Formula I that defines of claim 1, is selected from:
3. synthesize arbitrary the defined method belonging to the compound of general formula I of claim 1-2:
Compound II per is at low temperatures first through n-BuLi process, and the phenyl lithium obtained is again at BF 3et 2with (S)-polychlorinated dibenzo-furans generation substitution reaction under O catalysis, obtain compound III; Compound III and compound IV are reacted, and obtain compound V; Compound V obtains Compound I through oxidizing; As described in the definition of R is as arbitrary in claim 1-2.
4. the compound of Formula I that one of claim 1-2 defines is preparing the application in treatment diabetes B medicine.
CN201510409626.2A 2015-07-13 2015-07-13 Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof Pending CN104910083A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510409626.2A CN104910083A (en) 2015-07-13 2015-07-13 Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510409626.2A CN104910083A (en) 2015-07-13 2015-07-13 Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN104910083A true CN104910083A (en) 2015-09-16

Family

ID=54079583

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510409626.2A Pending CN104910083A (en) 2015-07-13 2015-07-13 Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN104910083A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699789A (en) * 2017-02-07 2017-05-24 广东赛博科技有限公司 Benzoquinazoline tyrosine kinase inhibitor containing cyanoaryl boronic acid as well as preparation method and application
CN106749368A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 The Benzoquinazole class tyrosine kinase inhibitor and purposes of a kind of amino-contained aryl boric acid
CN106749367A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor of amino-contained phenyl, Preparation Method And The Use
CN106749370A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 Benzoquinazole class tyrosine kinase inhibitor and purposes of one class containing aryl boric acid structure
CN106749369A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 The double ethoxy Benzoquinazole class Benzoquinazole class tyrosine kinase inhibitors of one class, Preparation Method And The Use
CN106831837A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 Aryl boric acid Benzoquinazole class tyrosine kinase inhibitor, Preparation Method And The Use of one class containing alkoxyphenyl radical
CN106831836A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor and purposes of nitrobenzene-containing base
CN106831834A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 A kind of Benzoquinazole class tyrosine kinase inhibitor and purposes containing nitroaryl boric acid
CN106831835A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 Tyrosine kinase inhibitor and purposes of one class containing the double ethyoxyl benzo quinazoline ditosylate salt structures of halo
CN106831838A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 Aryl boric acid and Benzoquinazole class tyrosine kinase inhibitor containing alkoxy substitution
CN106866715A (en) * 2017-02-07 2017-06-20 广东赛博科技有限公司 Benzoquinazole class tyrosine kinase inhibitor containing aryl boric acid structure, Preparation method and use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009212A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Niacin derivatives useful to treat metabolic syndromes
WO2010009210A2 (en) * 2008-07-17 2010-01-21 Schering Corporation Acetylsalicyclic acid derivatives useful to treat metabolic syndromes
CN102015026A (en) * 2008-05-05 2011-04-13 默克专利股份公司 Novel nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CN103724335A (en) * 2005-10-20 2014-04-16 默沙东公司 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724335A (en) * 2005-10-20 2014-04-16 默沙东公司 Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CN102015026A (en) * 2008-05-05 2011-04-13 默克专利股份公司 Novel nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2010009212A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Niacin derivatives useful to treat metabolic syndromes
WO2010009210A2 (en) * 2008-07-17 2010-01-21 Schering Corporation Acetylsalicyclic acid derivatives useful to treat metabolic syndromes

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699789A (en) * 2017-02-07 2017-05-24 广东赛博科技有限公司 Benzoquinazoline tyrosine kinase inhibitor containing cyanoaryl boronic acid as well as preparation method and application
CN106749368A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 The Benzoquinazole class tyrosine kinase inhibitor and purposes of a kind of amino-contained aryl boric acid
CN106749367A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor of amino-contained phenyl, Preparation Method And The Use
CN106749370A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 Benzoquinazole class tyrosine kinase inhibitor and purposes of one class containing aryl boric acid structure
CN106749369A (en) * 2017-02-07 2017-05-31 广东赛博科技有限公司 The double ethoxy Benzoquinazole class Benzoquinazole class tyrosine kinase inhibitors of one class, Preparation Method And The Use
CN106831837A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 Aryl boric acid Benzoquinazole class tyrosine kinase inhibitor, Preparation Method And The Use of one class containing alkoxyphenyl radical
CN106831836A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor and purposes of nitrobenzene-containing base
CN106831834A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 A kind of Benzoquinazole class tyrosine kinase inhibitor and purposes containing nitroaryl boric acid
CN106831835A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 Tyrosine kinase inhibitor and purposes of one class containing the double ethyoxyl benzo quinazoline ditosylate salt structures of halo
CN106831838A (en) * 2017-02-07 2017-06-13 广东赛博科技有限公司 Aryl boric acid and Benzoquinazole class tyrosine kinase inhibitor containing alkoxy substitution
CN106866715A (en) * 2017-02-07 2017-06-20 广东赛博科技有限公司 Benzoquinazole class tyrosine kinase inhibitor containing aryl boric acid structure, Preparation method and use

Similar Documents

Publication Publication Date Title
CN104910083A (en) Alkoxylphenyl triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application thereof
CN105025898B (en) Histamine H4The yl pyrimidines conditioning agent of benzimidazole 2 of acceptor
CN108463222A (en) Heterocyclic compound for treating disease
CN110862422B (en) Synthesis method of beta-galactosamine nitrogen glycoside and application of beta-galactosamine nitrogen glycoside in pharmacy
TW474931B (en) 3-amidochromanylsulfonyl(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them
CN105601650B (en) Structure, the preparation and use of diethylenetriamine base Chinese blister beetle acid imide dimer derivate
JPH07507792A (en) Novel steroids having a pregnane skeleton, pharmacological preparations containing them, and methods for their production
CN104961696A (en) Halobenzene triazole sulfoxide 11beta-HSD1 inhibitor, preparation method and application
CN104987312A (en) Aminobenzene triazole sulfoxide 11 beta-HSD1 inhibitor and application thereof
CN105001171A (en) Nitrobenzene triazole sulphoxides 11[beta]-HSD1 inhibitor and application of same
CN105017170A (en) Cyanobenzotriazole sulfoxide 11 beta-HSD1 inhibitors and use thereof
CN104987313A (en) Terminal-substituted triazole sulfoxide compound, preparation method thereof and application thereof
CN105037285A (en) Triazole sulfoxide type 11beta-HSD1 inhibitor, and preparation method and application thereof
CN104910084A (en) Terminal amido replaced triazole sulfoxide, preparation method and application thereof
CN105001170A (en) Triazole sulfoxide compound substituted by terminal nitrile group, preparation method and application of same
CN104961698A (en) Triazole sulfoxide compound with tail end substituted by nitro group, preparation method thereof and application thereof
CN104961697A (en) Triazole sulfoxide compound with tail end substituted by halogen as well as a preparation method and an application thereof
JP2021506826A (en) Crystal form, salt form and production method of 4- (naphthalene-1-yl) -4H-1,2,4-triazole compound
CN104974080A (en) 11beta-HSD1 (11-beta-hydroxysteroid dehydrogenase 1) inhibitor containing bipyridine tertiary alcohol structure as well as preparation method and application thereof
CN105001150A (en) 11 beta-HSD1 inhibitor of alkoxy bipyridine tertiary alcohol structure, preparation method and application thereof
CN105001152A (en) 11 beta-HSD1 inhibitor of dimethylamino bipyridine tertiary alcohol structure and application thereof
CN104974103A (en) Compound containing benzisoxazole and alcoxylphenyl structure and application thereof
CN104945315A (en) 11 beta-HSD1 inhibitor of nitro-bipyridine tertiary alcohol structure and application of inhibitor
CN105017135A (en) 11 beta-HSD1 inhibitor with dipyridyl-tert-alcohol structure and its preparation method and use
CN104974084A (en) 11beta-HSD1 (11-beta-hydroxysteroid dehydrogenase 1) inhibitor containing aminobipyridine tertiary alcohol structure and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150916